MX2022005813A - Formas de dosificacion novedosas de rofecoxib y métodos relacionados. - Google Patents

Formas de dosificacion novedosas de rofecoxib y métodos relacionados.

Info

Publication number
MX2022005813A
MX2022005813A MX2022005813A MX2022005813A MX2022005813A MX 2022005813 A MX2022005813 A MX 2022005813A MX 2022005813 A MX2022005813 A MX 2022005813A MX 2022005813 A MX2022005813 A MX 2022005813A MX 2022005813 A MX2022005813 A MX 2022005813A
Authority
MX
Mexico
Prior art keywords
rofecoxib
dosage forms
related methods
novel dosage
novel
Prior art date
Application number
MX2022005813A
Other languages
English (en)
Spanish (es)
Inventor
Raymond D Skwierczynski
Bradford C Sippy
Travis E Helm
Original Assignee
Tremeau Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tremeau Pharmaceuticals Inc filed Critical Tremeau Pharmaceuticals Inc
Publication of MX2022005813A publication Critical patent/MX2022005813A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022005813A 2019-11-13 2020-11-12 Formas de dosificacion novedosas de rofecoxib y métodos relacionados. MX2022005813A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962934898P 2019-11-13 2019-11-13
US202063018136P 2020-04-30 2020-04-30
US16/867,514 US10945992B1 (en) 2019-11-13 2020-05-05 Dosage forms of rofecoxib and related methods
PCT/US2020/060152 WO2021097038A1 (en) 2019-11-13 2020-11-12 Novel dosage forms of rofecoxib and related methods

Publications (1)

Publication Number Publication Date
MX2022005813A true MX2022005813A (es) 2022-08-16

Family

ID=74870322

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005813A MX2022005813A (es) 2019-11-13 2020-11-12 Formas de dosificacion novedosas de rofecoxib y métodos relacionados.

Country Status (9)

Country Link
US (5) US10945992B1 (cg-RX-API-DMAC10.html)
EP (1) EP4058012A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023502941A (cg-RX-API-DMAC10.html)
KR (1) KR20220123224A (cg-RX-API-DMAC10.html)
CN (1) CN115605197A (cg-RX-API-DMAC10.html)
CA (1) CA3155900A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022005813A (cg-RX-API-DMAC10.html)
TW (1) TW202128144A (cg-RX-API-DMAC10.html)
WO (1) WO2021097038A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210124188A (ko) * 2018-11-21 2021-10-14 트루모 파마슈티칼스, 인크. 정제된 형태의 로페콕시브, 제조 및 사용 방법
US20200323830A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with etoricoxib
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof
WO2023059698A1 (en) * 2021-10-06 2023-04-13 Tremeau Pharmaceuticals, Inc. Methods and compositions for treating von willebrand's migraine disorder

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21042A (en) 1858-07-27 yerby
US21647A (en) 1858-10-05 Construction of animal-traps
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
MY119407A (en) 1993-06-24 2005-05-31 Merck Frosst Canada Inc 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5h)-furanone as a cox-2 inhibitor.
AU1269495A (en) 1994-01-10 1995-08-01 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors
US5585504A (en) 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
DE69512930T2 (de) 1994-10-27 2000-05-18 Merck Frosst Canada & Co., Halifax Stilben-derivate verwendbar als cyclooxygenase-2 hemmer
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
AU3004997A (en) 1996-05-17 1997-12-09 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
GB9615867D0 (en) 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
JP4659190B2 (ja) 2000-08-31 2011-03-30 アンリツ株式会社 波形測定装置
US20040186155A1 (en) * 2003-01-30 2004-09-23 Dayno Jeffrey Marc Combination therapy for the treatment or prevention of migraine
ES2214129B1 (es) 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
US20070099926A1 (en) * 2003-07-02 2007-05-03 Rodger Ian W Combination therapy for treating chronic inflammatory diseases
WO2005016906A1 (en) 2003-08-14 2005-02-24 Shasun Chemicals And Drugs Limited Process for the manufacture of rofecoxib
TR200301552A1 (tr) 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
US9763912B2 (en) * 2013-10-30 2017-09-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions, methods of use, and methods of treatment
CN104173359B (zh) * 2014-09-05 2017-05-03 罗国安 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用
CN107614061A (zh) * 2014-12-01 2018-01-19 阿科莱尔斯疗法公司 用于治疗与疼痛有关的偏头痛和病症方法和组合物
WO2019193417A1 (en) 2018-04-05 2019-10-10 Kossen Co., Ltd. Composition and method of reducing joint pain associated with hemarthrosis
KR20210124188A (ko) 2018-11-21 2021-10-14 트루모 파마슈티칼스, 인크. 정제된 형태의 로페콕시브, 제조 및 사용 방법

Also Published As

Publication number Publication date
US20220409575A1 (en) 2022-12-29
US10945992B1 (en) 2021-03-16
CA3155900A1 (en) 2021-05-20
CN115605197A (zh) 2023-01-13
US20210137878A1 (en) 2021-05-13
WO2021097038A1 (en) 2021-05-20
US20210169845A1 (en) 2021-06-10
KR20220123224A (ko) 2022-09-06
JP2023502941A (ja) 2023-01-26
EP4058012A1 (en) 2022-09-21
US20220047542A1 (en) 2022-02-17
TW202128144A (zh) 2021-08-01

Similar Documents

Publication Publication Date Title
GB2595776B (en) Therapeutic solid dosage forms
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
EP4302835A3 (en) Methods of treating ovarian cancer
PH12018501001A1 (en) Therapeutic compositions for treatment of human immunodeficiency virus
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
IN2014CH00247A (cg-RX-API-DMAC10.html)
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
EP3970712A3 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
MX2017006454A (es) Administracion sublingual de riluzol.
MX2017006446A (es) Administracion sublingual de riluzol.
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
IL289338B1 (en) Therapeutic interactions of leucomethylthioninium
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения
IL281166A (en) Methods for using the phenoxypropylamine compound to treat pain
ZA201906153B (en) Pharmaceutical compositions for combination therapy
BR112022008856A2 (pt) Terapia combinada para doenças musculares
PH12020500045A1 (en) Novel composition of enzalutamide oral dosage form and method of manufacturing thereof
JOP20230099A1 (ar) تركيبات صيدلية
MX2017006205A (es) Tratamiento de la intoleracia a la alimentacion enteral.
JOP20200104A1 (ar) مركبات مثبطة لـ btk
MX2021003302A (es) Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
GB201812861D0 (en) Methods of administering therapy
MX387059B (es) Compuestos de benzo-n-hidroxi amida que tienen actividad antitumoral.